Skip to content
Study details
Enrolling now

Bintrafusp Alfa and PDS01ADC Trial

National Cancer Institute (NCI)
NCT IDNCT04235777ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

100

Study length

about 7.4 years

Ages

18–120

Locations

1 site in MD

About this study

Researchers are testing a treatment with M7824, PDS01ADC, and SBRT to see if it can help fight cancer that has spread. Participants will receive these treatments through injections and infusions over several months while also providing samples for research purposes. The trial will last approximately 2 years.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Receive Stereotactic body radiation therapy (SBRT)
  • 2.Take M7824
  • 3.Take PDS01ADC
PhasePhase 1
Primary goalsafety and tolerability of PDS01ADC and M7824 alone or in combination with SBRT

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: safety and tolerability of PDS01ADC and M7824 alone or in combination with SBRT

Secondary: Objective response rate (ORR), Overall Survival (OS), Progression free survival (PFS)

Body systems

Oncology